About US
Contact us
-
With approval supplement on deck, Reata dives into launch of its first commercial product SkyclarysWith a spring approval in hand, Reata Pharmaceuticals has been waiting patiently to launch its first commercial product, Skyclarys. Now,after an impurity problem stalled the rare disease med’s debut,2023/6/22
-
Andelyn Biosciences debuts cell and gene manufacturing headquarters in OhioAndelyn Biosciences, a cell and gene therapy CDMO,unveileda new manufacturing headquarters in Ohio, more than tripling its production footprint. The Andelyn Corporate Center in Columbus, Ohio, add2023/6/22
-
Lupin wins approval for first US generic of Boehringer Ingelheim's COPD blockbuster SpirivaLupin of India has become the first company toscoreapproval in the U.S. for its generic version of Boehringer Ingelheim’s blockbuster COPD treatment Spiriva HandiHaler. The2023/6/20
-
As Adderall shortages persist, Takeda's rival Vyvanse is now in short supplyMany months into the U.S. shortage of attention-deficit/hyperactivity disorder (ADHD) drug Adderall and its generics, a rival medicine from Takeda is now in short supply. In astatementon the Vyvan2023/6/20
-
Johnson & Johnson inks another Stelara patent settlement, this time with Alvotech and TevaAnother biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. market without a patent infringement challenge by early 2025 thanks to a new settlement. J&am2023/6/16
-
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved useAfter Ipsenmade a splashat this year's J.P. Morgan Healthcare Conference by scooping up liver disease specialist Albireo Pharma, the centerpiece of the buyout, Bylvay, has won a coveted label expansi2023/6/16
-
With FTC eyeing biopharma M&A deals, Pfizer refiles paperwork for $43B buyout of SeagenAn FTC lawsuit aimed atblockingAmgen’s $27.8 billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in t2023/6/13
-
Sanofi goes 'all in' on AI with new app to support company's manufacturing, R&D and moreSanofi is jumping on the artificial intelligence boat with a new app and a pledge to become “the first pharma company powered by artificial intelligence at scale.” The app, called plai and develop2023/6/13
-
FDA sets the stage for adcomm on Sanofi, AZ's RSV prospect later this weekAs GSK and Pfizer look to roll out their adultrespiratory syncytial virus (RSV) vaccines later this year, Sanofi and AstraZeneca hope to join them on the market with an antibody designed to protect i2023/6/8
-
Novo Holdings, Gurnet Point team up to buy antibiotics maker Paratek for $462MNovo Holdings and Gurnet Point have added antibiotics maker Paratek Pharma to their fold in a biopharma M&A deal worth approximately $462 million. The two investment firms willsnap up2023/6/8